Calamos Advisors’s EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant EQHA.U Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-300,700
Closed -$2.82M 1515
2022
Q2
$2.82M Hold
300,700
0.01% 860
2022
Q1
$2.98M Hold
300,700
0.01% 837
2021
Q4
$2.98M Hold
300,700
0.01% 826
2021
Q3
$3.01M Hold
300,700
0.01% 714
2021
Q2
$3M Hold
300,700
0.01% 661
2021
Q1
$2.98M Buy
+300,700
New +$3.05M 0.02% 640

Other funds holding EQHA.U

Calamos Advisors's EQHA.U Position: Q3 2022 in Review

Calamos Advisors sold out of EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant (EQHA.U) in Q3 2022, closing a stake of 300,700 shares — an estimated $2.82M sold.

Calamos Advisors first reported a position in EQHA.U in Q1 2021 and held it in 6 quarters. The position peaked at $3.01M in Q3 2021. 13 funds tracked by Wall St. Rank hold EQHA.U as of Q3 2022.

  • Calamos Advisors reported no remaining EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant position as of Q3 2022 after selling out during the quarter.
  • Calamos Advisors sold 300,700 EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant shares in Q3 2022, an estimated $2.82M.
  • Calamos Advisors first reported a position in EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant in Q1 2021 and held it in 6 quarters.
  • Calamos Advisors's EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant position peaked at $3.01M in Q3 2021.
  • 13 funds tracked by Wall St. Rank held EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant as of Q3 2022.

Based on Calamos Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.